LENSAR, Inc. has provided an update on its acquisition by Alcon Research, LLC, confirming that the transaction remains under regulatory scrutiny at the Federal Trade Commission. The company disclosed that it has received a Second Request for Additional Information from the FTC, a procedural step that extends the agency's review period as it conducts a more detailed antitrust analysis of the proposed deal.
Despite the extended review timeline, LENSAR maintains its expectation that the acquisition will close during the first half of 2026, contingent upon receiving necessary regulatory clearance and satisfaction of other closing conditions. The Second Request indicates the FTC is conducting heightened due diligence into competitive implications of the combination, which is a standard part of the review process for acquisitions in regulated industries such as ophthalmology and medical devices.
The transaction represents Alcon's continued expansion in the surgical technology sector. Both companies are working cooperatively with regulatory authorities to complete the review process and meet the anticipated closing timeline.